Health Economic Impact of First Pass Success: An Asia-Pacific Cost Analysis of the ARISE II Study.

"Leonard Yeo is a consultant for Stryker and See-mode. Leonard Yeo has equity in Cereflo; Osama O. Zaidat is a consultant for Neuravi, Stryker, Penumbra, and Medtronic; Jeffrey L. Saver is an employee of the University of California, which holds a patent on retriever devices for stroke. The University of California, Regents receives funding for Jeffrey L. Saver’s services as a scientific consultant regarding trial design and conduct to Covidien/Medtronic and Stryker. Jeffrey L. Saver serves as a consultant (modest) for Abbott, Medtronic, Stryker, and Neuravi/Cerenovus. Jeffrey L. Saver also has contracted stock options (modest) for Rapid Medical; Heinrich P. Mattle reports personal fees from Covidien/ Medtronic, personal fees from Neuravi/Cerenovus, personal fees from Servier, and personal fees from Bayer outside the submitted work; served on the steering committees of the SWIFT PRIME and ARISE studies; Stephanie Hsiao Yu Lee and Emilie Kottenmeier are employees of Johnson and Johnson; Heather L. Cameron and Rana A. Qadeer are paid consultants for Cerenovus; Tommy Andersson is a consultant for Neuravi/Cerenovus, Anaconda, Amnis Therapeutics, and Rapid Medical; served on the steering committees of the ARISE studies."

"This study was funded by Cerenovus, a subsidiary of Johnson and Johnson."